ImpediMed boosts cash by $1.2m with R&D refund

ImpediMed Limited announced today the receipt of an AUD 1.2 million R&D tax incentive refund. This refund is for eligible research and development activities undertaken during the financial year ended June 30, 2025.

The refund is expected to bolster ImpediMed's cash position, providing support for the ongoing development and commercialization of its SOZO® digital health platform. This financial boost follows the company's Q2 FY26 cash balance, which stood at AUD 23.0 million as of October 30, 2025.

ImpediMed, an Australian medical technology company with US and European operations, specializes in bioimpedance spectroscopy (BIS) technology. Its SOZO® platform, which is FDA-cleared and CE-marked, is used for multiple indications, including lymphoedema and heart failure, and is sold globally.